MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$92,100,000
Net Income
-$31,087,000
Net Profit Margin
-33.75%
EPS
-$0.18
Unit: Dollar
Revenue Breakdown
Recorlev
Gvoke
Keveyis
Royalty Contract And Other Reven...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product revenue, net
92,100,000
83,127,000
85,807,000
74,380,000
Cost of goods sold
12,512,000
10,574,000
10,947,000
10,996,000
Research and development
10,669,000
8,783,000
7,874,000
7,483,000
Selling, general and administrative
61,035,000
53,144,000
47,502,000
46,459,000
Amortization of intangible assets
2,711,000
2,710,000
2,711,000
2,711,000
Total costs and expenses
86,927,000
75,211,000
69,034,000
67,649,000
Income from operations
5,173,000
7,916,000
16,773,000
6,731,000
Interest and other income
1,455,000
1,202,000
1,461,000
1,158,000
Loss on debt extinguishment, net
-30,782,000
-
0*
-
Debt refinancing costs
-
-
0*
0
Interest expense
6,947,000
6,884,000
7,153,000
7,268,000
Change in fair value of warrants
-
-
0*
0
Change in fair value of contingent value rights
-
-
0*
0
Total other expense
-36,274,000
-5,682,000
-5,692,000
-6,110,000
Net loss before income taxes
-31,101,000
2,234,000
11,081,000
621,000
U.s. federal statutory tax rate
-
-
-29,000*
-
State and local income taxes, net of federal income tax effect
-
-
0*
-
Statutory tax rate difference between ireland and united states-IE
-
-
958,000*
-
Changes in valuation allowance-IE
-
-
1,515,250*
-
Other
-
-
12,250*
-
Statutory tax rate difference between ireland and united states-Foreign Tax Jurisdiction Other
-
-
72,500*
-
Subpart f income
-
-
-3,151,500*
-
Research and development tax credits
-
-
-306,000*
-
Changes in valuation allowance-US
-
-
928,000*
-
Compensation subject to the section 162 limitation
-
-
-319,000*
-
Stock compensation
-
-
-198,750*
-
Non-deductible expenses
-
-
-69,250*
-
Other adjustments
-
-
-24,500*
-
Income tax benefit
0
0
0
0
Net loss
-31,101,000
2,234,000
11,081,000
621,000
Unrealized gains (losses) on investments
-
-
0
0
Foreign currency translation adjustments
14,000
1,000
-
-1,000
Comprehensive loss
-31,087,000
2,235,000
11,081,000
620,000
Basic EPS
-0.18
0.01
0.067
0
Diluted EPS
-0.18
0.01
0.055
0
Basic Average Shares
172,823,455
170,523,208
166,145,512
163,649,932
Diluted Average Shares
172,823,455
177,631,154
201,448,225
177,617,307
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Recorlev
$56,780,000
(80.57%↑ Y/Y)
Gvoke
$22,549,000
(-3.91%↓ Y/Y)
Keveyis
$11,675,000
(1.65%↑ Y/Y)
Comprehensive loss
-$31,087,000
(-1513.23%↓ Y/Y)
Foreign currency
translation adjustments
$14,000
(1300.00%↑ Y/Y)
Product
$91,004,000
(34.41%↑ Y/Y)
Royalty Contract And
Other Revenue
$1,096,000
(-71.39%↓ Y/Y)
Net loss
-$31,101,000
(-1513.12%↓ Y/Y)
Product revenue, net
$92,100,000
(28.74%↑ Y/Y)
Net loss before
income taxes
-$31,101,000
(-1513.12%↓ Y/Y)
Income from operations
$5,173,000
(15.42%↑ Y/Y)
Total costs and
expenses
$86,927,000
(29.63%↑ Y/Y)
Total other expense
-$36,274,000
(-465.90%↓ Y/Y)
Interest and other income
$1,455,000
(53.48%↑ Y/Y)
Selling, general and
administrative
$61,035,000
(37.49%↑ Y/Y)
Cost of goods sold
$12,512,000
(5.16%↑ Y/Y)
Research and development
$10,669,000
(32.45%↑ Y/Y)
Amortization of intangible
assets
$2,711,000
(0.00%↑ Y/Y)
Loss on debt
extinguishment, net
-$30,782,000
Interest expense
$6,947,000
(-5.59%↓ Y/Y)
Buy us a coffee
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)